ADPT stock forecast
Our latest prediction for Adaptive Biotechnologies Corp.'s stock price was made on the Jan. 29, 2020 when the stock price was at 30.94$.
In the short term (2weeks), ADPT's stock price should underperform the market by -2.42%. During that period the price should oscillate between -9.25% and +8.25%.
In the medium term (3months), ADPT's stock price should underperform the market by -7.67%. During that period the price should oscillate between -32.94% and +21.42%.Get email alerts
About Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
At the moment the company generates 78M USD in revenues.
On its last earning announcement, the company reported a loss of -0.50$ per share.
The book value per share is 2.38$
Three months stock forecastJan. 29, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|